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Increase in vascular permeability occurs under 
many physiological conditions such as wound 
repair, inflammation, and thrombotic reactions, 
and is central in diverse human pathologies, in-
cluding tumor-induced angiogenesis, ocular dis-
eases and septic shock. Thrombin is a pro-
coagulant serine protease, which causes the local 
loss of endothelial barrier integrity thereby 
enabling the rapid extravasation of plasma pro-
teins and the local formation of fibrin-containing 
clots. Available information suggests that throm-
bin induces endothelial permeability by promot-
ing acto-myosin contractility through the 
Rho/ROCK signaling pathway. Here, we took 
advantage of pharmacological inhibitors, knock-
down approaches, and the emerging knowledge 
on how permeability factors affect endothelial 
junctions to investigate in detail the mechanism 
underlying thrombin-induced endothelial per-
meability. We show that thrombin signals 
through PAR-1 and its coupled G proteins Gα12/13 
and Gα11/q to induce RhoA activation and intra-
cellular calcium elevation, and that these events 
are interrelated. In turn, this leads to the stimula-
tion of ROCK, which causes actin stress-fiber 
formation. However, this alone is not sufficient to 
account for thrombin-induced permeability. In-
stead, we found that PRK, a Rho-dependent se-
rine/threonine kinase, is activated in endothelial 
cells upon thrombin stimulation, and that its ex-
pression is required for endothelial permeability 
and the remodeling of cell-extracellular matrix 
and cell-cell adhesions. Our results demonstrate 
that the signal initiated by thrombin bifurcates at 
the level of RhoA, to promote changes in the cy-
toskeletal architecture through ROCK, and the 
remodeling of focal adhesion components 
through PRK. Ultimately, both pathways con-
verge to cause cell-cell junction disruption and 
provoke vascular leakage. 
 
Endothelial homeostasis and vascular integrity are 
tightly regulated during normal angiogenesis, wound 
repair, thrombotic and inflammatory reactions (1). 
The vascular wall controls the exchange of macro-
molecules and fluid between blood compartment and 
interstitial tissue (2). Whereas pro-angiogenic path-
ways had been extensively studied, as part of efforts 
to understand normal and aberrant angiogenesis, the 
molecular mechanisms involved in the vascular bar-
rier permeability, and their implications in aberrant 
angiogenesis are still much less understood. For 
example, VEGF (Vascular endothelial growth fac-
tor), first described as Vascular Permeability Factor 
(VPF) acts by a biochemical route that involve the 
sequential activation of VEGF-receptor 2 
(VEGFR2), the kinase Src, the guanine exchange 
factor Vav2, and the GTPase Rac and p21 activated-
kinase PAK (3-5). This pathway converges on the 
regulation of endothelial cell-cell junctions thereby 
causing their disruption by promoting the internali-
zation of the endothelial adherens junction protein, 
VE-cadherin (3,6,7). 
The coagulation protease, thrombin, which activates 
the PAR (protease-activated receptor) family of G-
protein coupled receptor (8) by proteolytic cleavage, 
represents another key regulator of the endothelial 
barrier function. It is well known that endothelial 
exposure to thrombin stimulation induces rapid mor-
phological and cytoskeletal changes, characterized 
by formation of actin stress fibers and endothelial 
gaps that could both be involved in the loss of endo-
thelial barrier integrity (9). Several studies support 
that RhoA activation downstream Gα12/13 coupled to 
PAR-1 is required for these cellular events (10-12). 
In addition, ROCK, myosin light chain (MLC) and 
actin-regulating proteins participate in thrombin-
triggered cytoskeletal reorganization and endothelial 
barrier disruption, most likely through the acto-
myosin contractility pathway (13-15). 
However, the intervening molecular mechanisms are 
probably more complex than this linear biochemical 
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route, as Gα11/q coupling and calcium signaling, as 
well as the calcium-activated kinases PKC, have also 
been shown to play a role in thrombin-induced actin 
stress fiber formation (16-22). In addition, microtu-
bule stability may also participate in cell contractility 
(23,24). Finally, RhoA activation may utilize down-
stream targets in addition to ROCK as, for example, 
some formin family proteins have been shown to 
contribute to thrombin-based endothelial cytoskele-
ton rearrangement (25,26). We therefore decided to 
investigate the thrombin-initiated molecular cascade 
leading to increased endothelial permeability using a 
siRNA-based knockdown approach for key signaling 
candidates. Here, we show that thrombin uses a bi-
partite coupling from PAR-1 involving both Gα11/q 
and Gα12/13, which causes RhoA activation. The sig-
nal downstream from RhoA in turn bifurcates to 
stimulate two serine/threonine kinases, ROCK and 
PRK (PKC-related kinase). These RhoA down-
stream effectors then contribute to acto-myosin cell 
contractility, by regulating actin stress fiber forma-
tion and focal adhesion organization, respectively. 
Finally, these pathways converge to promote the 
redistribution of endothelial cell-cell junctions, and 
the disruption of VE-cadherin adhesion by a me-
chanism distinct from that triggered by VEGF stimu-
lation. These findings may help to dissect the mole-
cular mechanisms deployed by thrombin causing the 
loss of endothelial barrier integrity, which may faci-
litate the future development of anti-permeability 
agents in thrombotic reactions. 
 
EXPERIMENTAL PROCEDURES 
 
Cell culture and transfections—Immortalized human 
vascular endothelial cells were obtained from (27), 
and cultured in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum (Sigma, 
Saint-Louis, MO). DNA transfections of pCEFL-
mock, pCEFL-Gα11, -Gα12, -Gα13, -Gαq wild-type or 
activated QL mutants (21), pCEFL-ROCK-KD (ki-
nase dead) mutant (28) were performed using the 
Amaxa's electroporation system (Amaxa Biosys-
tems, Gaithersburg, MD). Non-silencing control 
RNA sequences (nsi) and Gα11, Gα12, Gα13, Gαq and 
PRK1 silencing RNA duplexes (siRNA, Qiagen, 
Valencia, CA) were transfected twice, on day 1 and 
day 3, using the Hiperfect reagent (Qiagen) and har-
vested after 5 days. 
Reagents and antibodies—Recombinant human 
VEGF and IL-8 were purchased from PeproTech 
(Rocky Hill, NJ), thrombin was purchased from 
Sigma, as well as ionomycin, BAPTA-AM (1,2-Bis 
2-aminophenoxy ethane-N,N,N′,N′-tetraacetic acid 
tetrakis acetoxymethyl ester), 2-ABP (2-amino-1-
hydroxybutylidene-1,1-bisphosphonic acid), TMB-8 
(3,4,5-trimethoxybenzoic acid 8-diethylamino-octyl 
ester), lanthanade, verapamil (5-N-3,4-
dimethoxyphenylethylmethylamino-2-3,4-dimethox-
yphenyl-2-isopropylvaleronitrile hydrochloride), and 
ML-7 (1-5-iodonaphthalene 1-sulfonyl 1H-
hexahydro 1,4-diazepine hydrochloride). Pertussis 
toxin, botulinum coenzyme C3 toxin and tetanolysin 
were from List Biologicals Labs (Campbell, CA), 
blebbistatin (1-Phenyl 1,2,3,4-tetrahydro 4-
hydroxypyrrolo 2.3-b-7-methylquinolin 4-one) and 
Y27632 from Calbiochem (San Diego, CA). 
SCH79797 Par-1 and TCY-NH2 Par-3/4 inhibitors 
were from Tocris (Ellisville, MO), FSLLRY-NH2 
Par-2 from Peptides International (Louisville, KY). 
The following antibodies were used: anti-paxillin 
(BD Biosciences, San Jose, CA), anti-phospho-
extracellular regulated kinases ERK1/2, phospho-
Y118 paxillin, phospho-S19 Myosin Light Chain 
(MLC), phospho-T774/T816 PRK1/2, and phospho-
S3 cofilin (Cell Signaling, Boston, MA), anti-myc 
(Covance, Princeton, NJ), anti-phospho-tyrosine 
(4G10, Millipore, Waltham, MA), anti-phospho-
Y397 Focal Adhesion Kinase FAK (BioSource, In-
vitrogen, Camarillo, CA), anti-ZO-1 (Zymed, Invi-
trogen), anti-tubulin, extracellular related kinase 
ERK1, Gα11, Gα12, Gα13, Gαq, RhoA, PRK1 and VE-
cadherin (Santa Cruz Biotech, Santa Cruz, CA), anti-
β-catenin (Sigma), anti-phospho-S665 VE-cadherin 
(3), and anti-β-arrestin2 (29). 
Cytosolic calcium measurements—Changes in intra-
cellular Ca2+ levels were assessed using Fluo-4 NW 
calcium indicators from Invitrogen, following the 
manufacturer’s instructions. Fluorescence was read 
in 96-well plate format at room temperature, using 
appropriate settings (Ex/Em 494/516 nm, Optima 
BMG Labtech, Durham, NC). 
Permeability assays—In vitro permeability assays 
were conducted as described in (30), using 3 days-
old endothelial monolayers on collagen-coated 3 µm 
porous membranes (Transwell, Corning Costar, Ac-
ton, MA) and 60 kDa fluorescein-conjugated dextran 
(Invitrogen). Measurements were analyzed on a mul-
ti-plate fluorescent reader (Victor 3V1420, Perkin-
Elmer, Wellesley, PA). 
GST-pull downs, immunoprecipitations and western-
blot—Methods and buffers were all described in 
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(30). Membranes were scanned using the Odyssey 
Infra-Red Imaging System from Li-Cor BioSciences 
(Lincoln, NB). Alexa fluorescent dye-conjugated 
secondary antibodies were purchased from Invitro-
gen. 
VE-cadherin internalization assay and immunofluo-
rescence—VE-cadherin antibody uptake and immu-
nofluorescence staining protocols were described in 
(3,31). Secondary antibodies were from Jackson 
ImmunoResearch (West Grove, PA) and Alexa546-
conjugated phalloidin from Invitrogen. All confocal 
acquisitions were performed on a TCS/SP2 Leica 
microscope (NIDCR Confocal Facility, Bethesda, 
MD). 
Statistical analysis—Graphs are shown as a mean 
value + SEM from at least 3 independent experi-
ments, confocal pictures and western-blot scans are 
representative of at least 3 independent experiments. 
Statistical analysis was performed with the Prism 
software (ANOVA test, GraphPad), *** p<0.001, ** 
p<0.01, * p<0.05. 
 
RESULTS 
 
Thrombin induces endothelial permeability mainly 
through PAR-1
 
and Gα12/13/11/q coupling—Since mul-
tiple receptors for thrombin (PAR) might co-exist at 
the surface of endothelial cells, we first assessed 
which PAR was involved during the endothelial 
permeability response using competitive antagonists. 
Whereas blocking PAR-2, PAR-3 and PAR-4 only 
mildly affected thrombin-induced permeability, in-
terfering with PAR-1 signaling dramatically reduced 
it to its basal level (Fig. 1A). Interestingly, inhibition 
of ERK activation was achieved only when multiple 
PAR antagonists were used, suggesting that whereas 
several PARs can independently controlled ERK 
activation in endothelial cells, PAR-1 may play a 
more prominent role in initiating signaling events 
culminating in endothelial barrier disruption (Fig. 
1B). We then aimed at characterizing the Gα sub-
units responsible for the PAR-1-controlled permea-
bility. Initially, by the use of pertussis toxin which 
impedes Gαi signaling (32), we confirmed that 
thrombin-induced permeability was independent of 
Gαi, in contrast to IL-8, which acts through its cog-
nate Gαi-coupled receptor, CXCR2 (Fig. 1C). To 
determine whether Gα12/13 or Gα11/q subunits are 
instead involved, we first utilized a molecular mu-
tant approach, where dominant active forms were 
transfected in endothelial cells (Fig. 1D). Interesting-
ly, the expression of activated forms of Gαq and Gα11 
was sufficient to increase endothelial permeability in 
non-stimulated cells (Fig. 1E). However, all Gα12, 
Gα13, Gα11 and Gαq dominant active forms were able 
to potentiate thrombin-induced junctional permeabil-
ity (Fig. 1F), suggesting a complex coupling of PAR 
receptors in the endothelial barrier function. Impor-
tantly, they did not alter the response to VEGF, a 
pro-permeability factor that acts through a tyrosine-
kinase receptor (Fig. 1F). To understand better the 
specificity of PAR receptors signaling in endothelial 
permeability regulation, we next investigate the con-
tribution of each Gα subunits by siRNA-based 
knockdown approaches (Fig. 1G). This revealed that 
Gα11 and Gαq were both required for thrombin to 
increase endothelial permeability, while Gα12 and 
Gα13 only partially affected the amplitude of the 
permeability response. Thus, our data suggest that 
thrombin can increase endothelial permeability 
mainly through PAR-1 coupled to Gα11/q, and to a 
lesser extent through Gα12/13. 
Gα11/q-induced calcium entry is required for throm-
bin signaling in permeability—Gα11/q-coupled recep-
tors can generally increase intracellular calcium 
concentrations, thus triggering multiple signaling 
pathways. Indeed, as previously reported, thrombin 
provoked a rapid increase in intracellular Ca2+ con-
centration (Fig. 2A)(16). This calcium wave was 
strictly dependent on the presence of Gα11/q, but not 
of Gα12/13, as judged by the calcium flux in cells in 
which specific Gα subunits was knocked down, 
alone or in combination (Fig. 2B). We thus explored 
the role of calcium entry in endothelial permeability. 
We first used different chemical inhibitors with dis-
tinct mode of action. BAPTA-AM, a general diva-
lent ion chelator, reduced the increase of endothelial 
permeability upon thrombin stimulation but also in 
response to VEGF, suggesting a broad-spectrum 
inhibition of essential calcium-dependent events 
(Fig. 1C). Interestingly 2-ABP and TMB-8, two 
different compounds blocking calcium release from 
intracellular compartment storage (33), did not mod-
ify endothelial permeability, whereas lanthanade and 
verapamil, which both affect extracellular Ca2+ in-
flux through plasma membrane receptor-operated 
calcium channels (16), dramatically prevented 
thrombin-induced permeability (Fig. 1C). Thus, 
these data suggest that thrombin can trigger an in-
crease in intracellular calcium concentration by the 
activation of receptor-operated calcium channels on 
endothelial cells, which is in turn necessary for the 
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endothelial barrier control. As it is well described 
that vascular permeability increase by thrombin is 
mediated by RhoA activation (9,16), we asked 
whether calcium increase and RhoA activity were 
linked. Interestingly, we first observed that in endo-
thelial cells both Gα12/13 and Gα11/q protein subunit 
family contribute to RhoA activation by thrombin 
(Fig. 2D). Moreover, when the increase in intracellu-
lar calcium concentration was halted by the use of 
lanthanade or chelated by BAPTA-AM, thrombin-
induced RhoA activation was barely detectable (Fig. 
2E). Instead, 2-ABP, which affects storage-operated 
calcium, did not alter RhoA activation, in agreement 
with its lack of effect on endothelial permeability. In 
line with these results, myosin light chain (MLC) 
phosphorylation, a downstream target of RhoA, was 
similarly prevented by BAPTA-AM and lanthanade 
(Fig. 2E). Together, these findings suggest that 
thrombin stimulates Gα11/q to promote calcium entry, 
which in turn cooperates with Gα12/13 to stimulate 
RhoA activation and endothelial permeability. 
ROCK and PRK are both required for thrombin-
induced permeability—Since RhoA is an essential 
mediator for thrombin-triggered permeability 
through both Gα12/13 and Gα11/q, we examined in 
more detail the mechanisms involved in endothelial 
permeability downstream from RhoA. First, we ob-
served that the inhibition of RhoA activation by C3 
toxin blocked thrombin-induced permeability, while 
VEGF function was not affected (Fig. 3A). In addi-
tion, the use of Y27632, a well characterized inhibi-
tor of ROCK and PRK (34), two serine/threonine 
kinases acting downstream of RhoA, hampered the 
thrombin-induced permeability response (Fig. 3A). 
The chemical inhibition of RhoA-dependent cy-
toskeletal contractility by ML7 and blebbistatin, 
which inhibit MLC kinase and myosin II, respective-
ly, also prevented the increase in endothelial per-
meability caused by thrombin, while mildly affect-
ing the effect of VEGF (Fig. 3B). These observa-
tions are aligned with the role of cell contractility in 
endothelial permeability upon thrombin activity (9). 
To assess the specific contribution of ROCK and 
PRK in this RhoA-initiated contractility-dependent 
pathway, we decided to knockdown PRK expression 
by the use of siRNA and to abolish ROCK activity 
by the expression of its dominant-negative mutant 
(ROCK-KD). The latter was found to be a more 
effective approach to prevent ROCK function than 
knocking down ROCK, which was only limited us-
ing multiple siRNAs (data not shown). As reported 
earlier, ROCK is required for thrombin-dependent 
permeability increase (Fig. 3C)(14). Surprisingly, we 
found that PRK is also necessary for this response, 
as siRNA extinction of PRK expression prevented 
from thrombin-induced permeability (Fig. 3C). 
Thus, both RhoA downstream targets, ROCK and 
PRK are required for the endothelial barrier destabi-
lization caused by thrombin exposure.  
ROCK and PRK control separately thrombin-
induced contractility pathways—We then aimed at 
understand better the specific contribution of each 
RhoA target in the regulation of the endothelial bar-
rier by thrombin. Among the many mediators of cell 
contractility, actin polymerization, stress fiber for-
mation and focal adhesion attachment play essential 
roles in endothelial cell function (35). Thus, we ex-
plored the impact of PRK and ROCK on these mul-
tiple cellular events. First, in the absence of PRK 
expression, we observed that thrombin-induced 
phosphorylation of cofilin and MLC were not al-
tered, while FAK and paxillin phosphorylations 
were severely reduced (Fig. 4A-C). These data indi-
cated that PRK is essential for thrombin-regulated 
phosphorylation of focal adhesion components. On 
the contrary, blockade of ROCK activity impeded 
cofilin and MLC phosphorylation, which mediate 
actin polymerization, but leaving intact the levels of 
activation of paxillin and FAK (Fig. 4B-C). To fur-
ther estimate the implication of ROCK and PRK on 
the contractility pathways at the level of actin stress 
fiber and focal adhesion formation, endothelial cells 
were prepared for immunostaining as described in 
(36). First, actin staining in endothelial monolayers 
showed a regular pattern of actin aligned at cell-cell 
contact area. Thrombin induced a massive formation 
of actin stress fibers, and opening of the cell-cell 
junctions in agreement with its effect on endothelial 
permeability (Fig. 4D). However, PRK siRNA and 
ROCK-KD expression altered these morphological 
changes, as shown by actin labeling with phalloidin 
and the quantification of the number of actin stress 
fibers (Fig. 4E). Similarly, we analyzed the status of 
focal adhesion by paxillin staining. Interestingly, the 
number of paxillin clusters was reduced in PRK 
siRNA-treated cells (Fig. 4F). While found aligned 
to sparse actin fibers perpendicular to the cell-cell 
contact borders, the morphology of paxillin staining 
was dramatically altered, including their size, sug-
gesting an abortive attachment of endothelial cells to 
the extracellular matrix in the absence of PRK (Fig. 
4G). Our observations further support the emerging 
5 
 
role of PRK in the assembly and function of focal 
adhesions in endothelial cells exposed to thrombin. 
Conversely, ROCK-KD expression severely blocked 
the formation of actin cables crossing the cell (Fig. 
4D-E), while the morphology and the number of the 
paxillin clusters were barely modified (Fig. 4F-G). 
Altogether, our data support the notion of a two-
pronged regulation of acto-myosin contractility in 
response to thrombin exposure. In this model, RhoA 
stimulation triggers, PRK activation, which regulates 
focal adhesion components, and ROCK, which acts 
though MLC and cofilin to induce actin stress fiber 
formation. Both events ultimately cooperate to pro-
mote endothelial cell contractility and junctional 
permeability. 
ROCK and PRK-dependent contractility is involved 
in cell-cell contact remodeling—VEGF-induced 
permeability requires cell-cell junction remodeling 
(3,6,7). Our results prompted us to characterize how 
cell contractility could control junctional permeabili-
ty. First, we observed that thrombin stimulation was 
associated with the reorganization of VE-cadherin 
and ZO-1-containing contacts (Fig. 5A). When ana-
lyzed in more detail, we noticed that the VE-
cadherin staining-containing areas appeared larger 
upon VEGF stimulation, which can reflect overlap-
ping of membranes, ruffling or intracellular accumu-
lation at the vicinity of cell-cell contacts. Thrombin 
exposure resulted in a slightly different morphology, 
as VE-cadherin staining looked more stretched as the 
cell-cell junctions were disrupted (Fig. 5A). We can 
speculate that thrombin may use a contractility-
based mechanism that tears apart cell-cell junctions, 
whereas VEGF may deploy signaling pathways re-
sulting in a more subtle effect, involving VE-
cadherin redistribution and membrane remodeling 
(3,5,37,38). In this context, VE-cadherin endocytosis 
was markedly increased upon VEGF exposure while 
enhanced by a fold above the basal level by throm-
bin (Fig. 5B). In addition, while both permeability 
factors led to tyrosine phosphorylation of VE-
cadherin and reduction of VE-cadherin/β-catenin 
interaction, only VEGF promoted S665 phosphory-
lation of VE-cadherin and its further interaction with 
β-arrestin (Fig. 5C), as a hallmark for VE-cadherin 
adhesion internalization (30,39,40). Finally, both 
ROCK and PRK blockade reduced the effects of 
thrombin on VE-cadherin junctions, as the overall 
organization of the endothelial monolayer appeared 
less disrupted (Fig. 5D). These observations suggest 
that VEGF and thrombin trigger divergent molecular 
mechanisms that may converge on the destabiliza-
tion of endothelial cell-cell junctions and loss of 
endothelial monolayer integrity. 
 
DISCUSSION 
 
Thrombin, a key pro-coagulant serine-protease, also 
regulates the adhesion and rolling of immune cells 
on the luminal face of blood vessel walls, and exerts 
a potent pro-angiogenic and pro-permeability action 
through endothelial expressed PARs. These G-
protein coupled receptors involve the activation of 
the small GTPase RhoA in endothelial cells in re-
sponse to thrombin (9,41). However, the intervening 
G protein subunits and the precise RhoA down-
stream targets by which thrombin acts are much less 
understood. Here, we show that thrombin-induced 
RhoA activation is coupled to Gα12/13 and to Gα11/q, 
and that the latter involves intracellular calcium con-
centration elevation. Furthermore, we show that the 
signaling pathway initiated by thrombin bifurcates 
downstream from RhoA, as it involves the activation 
of two serine-threonine Rho-regulated protein kinas-
es, ROCK and PRK, which in turn regulate the con-
traction of acto-myosin fibers and the organization 
of focal adhesions, respectively. Ultimately, both 
kinase-initiated biochemical routes cooperate to 
promote cell-cell junction remodeling and loss of 
endothelial monolayer integrity. 
Detailed genetic studies have revealed that thrombin 
activates RhoA through Gα12/13 and to a lesser extend 
Gαq/11 (9,42,43). Here, by using siRNA knockdown 
approaches, we show that in endothelial cells the 
expression of both Gα12 and Gα13 is required for the 
full activation of RhoA. In addition, Gαq and Gα11 
knockdown prevented RhoA activation by thrombin. 
This suggests that in endothelial cells the two fami-
lies of heterotrimeric G protein α subunits, Gα12/13 
and Gα11/q, play a complementary and non-
redundant role. In the case of the Gα12/13 family, they 
likely activate RhoA through guanine nucleotide 
exchange factor (GEF), such as p115-RhoGEF, 
PDZ-RhoGEF and leukemia-associated Rho GEF 
(LARG), which all exhibit a structural domain high-
ly related to that of regulators of G-protein signaling 
(RGS), whereby they bind Gα12/13 directly, leading to 
RhoA activation (44-47). In the case of Gα11/q, this 
G protein family may utilize GEFs such as p63 
RhoGEF and Trio (48,49), though it may also utilize 
LARG (50). Although which specific GEFs are in-
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volved in the RhoA activation by thrombin, and 
specifically how calcium elevation affects their ac-
tivity or that of Rho GAPs (GTPase activating pro-
teins), are yet to be determined. Nonetheless, the fact 
that coupling to Gα12/13 and Gα11/q are both required, 
suggests a dual, fine-tuned regulation of RhoA acti-
vation downstream of PAR stimulation. 
On the other hand, initial experiments using overex-
pression of RhoA mutants provided evidence of a 
role of its cycling activity in thrombin-induced endo-
thelial permeability (10,14). Combined with the use 
of Y27632 as a ROCK pharmacologic inhibitor, it 
was suggested that the Rho/ROCK nexus affects 
both actin stress fiber and endothelial junction or-
ganization in response to thrombin (10,14). In this 
regard, Y27632 can specifically inhibit the kinase 
activity of two Rho-downstream effectors, ROCK 
and PRK (34). Indeed, by using siRNA approaches 
and mutant overexpression, we confirmed the in-
volvement of ROCK, and revealed that PRK is an 
essential component of the signaling pathway dep-
loyed by thrombin to increase endothelial permeabil-
ity. Future works are still required to assess whether 
PRK-KD mutant might have similar effects than the 
abolition of its expression by siRNA, as multiple 
domains within PRK protein, beside its kinase ac-
tivity, might control downstream signaling events. In 
fact, we show here that the thrombin-induced signal-
ing bifurcates downstream from RhoA, and that 
ROCK and PRK contribute by complementary me-
chanisms to trigger actin stress fiber formation asso-
ciated with focal adhesions (Fig. 6). While MLC 
function and therefore the regulation of the acto-
myosin function are the most likely targets of ROCK 
in the mechanism by which thrombin induced stress 
fiber formation and cell contraction (13,35,51), 
PRK, also known as PKN, is a poorly studied but 
highly abundant RhoA target (52). PRK has been 
shown to play a role in actin and focal contact organ-
ization in response to lysophosphatidic acid (53,54). 
As speculated from the structural resemblance be-
tween the catalytic domain of PRK and PKC, PRK 
efficiently phosphorylates peptide substrates based 
on the pseudosubstrate sequence of PKC in vitro. 
Similarly, to the use of Y27632 that blocks both 
ROCK and PRK, the treatment with PKC inhibitors 
may have masked PRK implication in thrombin sig-
naling as well (34,41). In the context of thrombin-
induced endothelial permeability, our data strongly 
suggest that PRK is involved in the regulation of 
focal adhesion components. Indeed, the absence of 
PRK expression specifically hampered FAK and 
paxillin phosphorylation, and altered the morpholo-
gy of focal adhesions. However, the direct target of 
PRK kinase activity is still to be determined. One 
can speculate that the actin-binding protein, α-
actinin, might link PRK to focal adhesion in the 
thrombin-induced cytoskeletal changes in endotheli-
al cells, as α-actinin has been shown to interact with 
PRK (55). In addition to the control of PRK activity 
by RhoA binding (56,57), phosphoinositide 3-kinase 
and PDK1 signaling might contribute to PRK activa-
tion (58,59), therefore providing a likely explanation 
for the inhibitory activity of phosphoinositide 3-
kinase inhibitors on thrombin-induced signaling 
((41) and data not shown). 
Thrombin triggers the rapid contraction of the endo-
thelial monolayer (35,41). This acto-myosin contrac-
tility increase is suspected to regulate in turn cellular 
adhesion at the level of cell-to-extracellular matrix 
and cell-to-cell contacts (15,41); this contraction 
appears to be the driven force for cell-cell contacts 
disengagement and loss of the endothelial barrier 
integrity. Alternatively, acto-myosin contraction 
could trigger not only mechanical and cytoskeletal 
changes in endothelial cells, but could also lead to 
the redistribution of kinases and phosphatases within 
the cells. This mechanism might participate in the 
phosphorylation of VE-cadherin and associated pro-
teins in response to thrombin; such phosphorylation 
cascade is thought to disrupt cadherin-based cell-cell 
contacts (6,7,30,39,40). Of note, serine-dependent 
VE-cadherin internalization, which plays a central 
role in VEGF-induced vascular leakage (3,30), was 
slightly enhanced in thrombin-stimulated cells, sug-
gesting the existence of divergent mechanisms be-
tween VEGF and thrombin in the regulation of the 
endothelial barrier. 
In conclusion, while VEGF may promote endothelial 
cell permeability by a more linear signaling axis, the 
biochemical route by which thrombin induces the 
rapid loss of endothelial barrier integrity appears to 
involve a signaling network that involves multiple G 
proteins and their linked GEFs, which converges to 
activate RhoA, and that RhoA utilizes divergent 
molecular targets to promote the contraction of acto-
myosin and the formation and remodeling of focal 
contacts. Ultimately, this signaling network may 
enable thrombin receptors to orchestrate rapid and 
reversible cytoskeletal changes and the reorganiza-
tion of cell-matrix and cell-cell adhesion systems. 
Both mechanisms are required to facilitate junctional 
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permeability and the rapid extravasation of serum 
components, thereby initiating the production of 
provisional matrix, vascular wall thickening, and a 
pro-inflammatory phenotype. 
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FIGURE LEGENDS 
 
Fig. 1. Thrombin induces endothelial permeability through PAR-1 and Gα12/13 and Gα11/q heterotrimeric G protein 
subunits. 
A. Human endothelial cells were cultivated on collagen-coated 3 µm pore-size inserts for 3 days, starved over-
night and pre-treated with PAR antagonists (PARinh), for 4 hours at 1 µM (PAR1), 20 µM (PAR2) and 10 µM 
(PAR 3/4). Cells were then stimulated with thrombin (0.1 U/ml, 15 min) and incubated with 40 kDa FITC-dextran 
for 30 minutes more. Results are shown as the average + S.E.M. of the ratio between treated and untreated cells in 
3 independent experiments. B. Total cell lysates were extracted from similarly treated cells and subjected to phos-
pho-ERK1/2 and total ERK1 western-blots. C. As described in A, endothelial monolayers were incubated with 
pertussis toxin (PTX, 10 ng/ml) overnight before stimulation and permeability assay. Cells were stimulated with 
VEGF (50 ng/ml, 30 min), thrombin (0.1 U/ml, 15 min), and IL-8 (50 ng/ml, 30 min). D. Endothelial cells were 
electroporated with Gα12, Gα13, Gαq and Gα11, either wilt-type (WT) or constitutively active mutant (QL) and cell 
lysates were prepared 48 hours later. E-F. Similarly transfected cells were processed for permeability assays in 
non stimulated cells in E, or stimulated by VEGF (50 ng/ml, 30 min) or thrombin (0.1 U/ml, 15 min) in F. Bar 
graphs show the average + S.E.M. of the ratio between QL transfected cells and WT transfected cells for each Gα 
subnits. G. Endothelial cells were transfected with non-silencing (nsi) or siRNA sequences (50 nM, 5 days) target-
ing Gα12, Gα13, Gαq (2 independent sequences) and Gα11 (2 independent sequences). Protein lysates were analyzed 
for Gα12, Gα13, Gαq and Gα11 expression while Tubulin was used as a loading control. H. Similarly siRNA-treated 
cells were used for permeability assays in response to thrombin. All panels are representative of at least 3 inde-
pendent experiments. ANOVA test: *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Fig. 2. Gα11/q-induced calcium entry is required for Thrombin signaling in permeability. 
A. Intracellular calcium concentration was measured by the Fluo4 probe in overnight starved 3 days-old endo-
thelial monolayers and left unstimulated (buffer) or stimulated by ionomycin (1µM), thrombin (0.1 U/ml) and 
VEGF (50 ng/ml) for the indicated times. B. Similar experiments were performed in non-silencing (nsi) and 
Gα12/13, Gαq, Gα11 and Gαq/11 siRNA-treated cells. C. Human endothelial cells were cultivated on collagen-coated 
3 µm pore-size inserts for 3 days, starved overnight and pre-treated with the calcium chelator (BAPTA-AM, 25 
µM), the inhibitors of storage-operated calcium (SOCinh) flux (2-ABP, 75 µM and TMB-8, 100 µM), and the inhi-
bitors of receptor-operated calcium (ROCinh) flux (lanthanade, 250 nM and verapamil, 500 nM) for 30 min prior 
to thrombin stimulation and permeability assays. D. Human endothelial cells were transfected with non-silencing 
RNA (nsi) or Gα12/13, Gαq/11 and Gα12/13/q/11 (all 4) siRNA for 5 days. Overnight starved cells were non-stimulated 
(-) or stimulated by thrombin, and then subjected to RhoA pull-down assay to assess RhoA activation (RhoA-
GTP). Western-blots were performed in total cell lysates for the indicated G protein α subunits and RhoA. The 
level of RhoA-GTP was estimated on scanned membranes (Licor) and expressed as a normalized ratio on total 
RhoA. E. Overnight starved 3 days-old endothelial cells were treated with 25 µM BAPTA-AM (bapta), 75 µM 2-
ABP, and 250 nM lanthanade (lantha) prior to thrombin stimulation. RhoA activation was estimated in the Rho 
pull-down fraction (RhoA-GTP), and PRK and MLC phosphorylations (p) in total cell lysates. Total RhoA served 
as a loading control. All panels are representative of at least 3 independent experiments. ANOVA test: *, p<0.05; 
**, p<0.01; ***, p<0.001. 
 
Fig. 3. ROCK and PRK are both required for Thrombin-induced permeability. 
A-B. Permeability assays were done in 3 days-old human endothelial cell starved overnight and pre-treated with 
C3 toxin (1 µg/ml) with tetanolysin (20 units) for 16h,  Y27632 (45 min, 5, 10 and 50 nM), blebbistatin (45 min, 5 
µM) and ML-7 (45 min, 10 µM) prior VEGF and thrombin stimulation as described previously. C. Human endo-
thelial cells were electroporated with mock or myc-tagged ROCK-KD mutant and cultured for 3 days on collagen-
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coated inserts. Overnight starved cells were then stimulated with thrombin and further analyzed for permeability. 
Expression level of ROCK-KD was checked by western-blot against myc. D. Similarly, cells were transfected 
with non-silencing RNA (nsi, 3 days, 50 nM) or two independent sequences targeting PRK (si#1 and si#2, 3 days, 
50 nM). Extinction efficiency was checked by western-blot for PRK, and Tubulin was used as a loading control. 
All panels are representative of at least 3 independent experiments. Permeability assays were performed in each 
condition in non-stimulated (Ctrl), and VEGF and Thrombin-stimulated cells. ANOVA test: *, p<0.05; **, 
p<0.01; ***, p<0.001. 
 
Fig. 4. ROCK and PRK control distinct Thrombin-induced contractility pathways. 
A. Human endothelial cells were transfected with 50 nM non-silencing RNA (nsi) or two independent sequences 
targeting PRK (si#1 and si#2) for 3 days. Overnight starved cells were left unstimulated or simulated with throm-
bin (0.1 U/ml, 5 min) and total cell lysates were used for western-blot against phospho-specific (p) MLC, cofilin 
(Cof), paxillin (Pax), and FAK. siRNA knockdown was checked by PRK western-blot, Tubulin was used as a 
loading control. B. Similar experiments were performed in endothelial cells transfected with mock DNA or myc-
tagged ROCK-KD, whose expression level was checked by myc western-blots. C. The levels of phosphorylation 
of MLC, cofilin, (Cof), paxillin (Pax) and FAK were estimated on scanned membranes (Licor) from multiple ex-
periments and expressed as a normalized ratio on tubulin. D.  Nsi-, PRK siRNA- , mock- and ROCK-KD-
transfected human endothelial cells were grown on collagen-coated glass coverslips for 3 days as monolayers, 
starved overnight and then stimulated with thrombin. Non-transfected cells were left unstimulated and used as 
control (Ctrl). Actin cystoskeleton (red) was revealed by phalloidin labeling, focal adhesions (green) by anti-
paxillin immunostaining. Binary calculation (bin.) was applied on paxillin threshold pictures to unveil focal adhe-
sion morphology (Image J software). E. The number of cells presenting actin stress fibers was manually counted 
in 250 cells and expressed as the percentage of total cells in non-stimulated (ctrl) and nsi-, PRK siRNA- , mock- 
and ROCK-KD-transfected cells exposed to Thrombin. F-G. Similarly treated cells were analyzed by confocal 
microscopy and post-treated for binary processing on threshold pictures. Both the number of particles (F) and the 
average pixel size (G) were calculated for the paxillin-positive focal adhesions per field (n=9). All panels are rep-
resentative of at least 3 independent experiments. ANOVA test: *, p<0.05; **, p<0.01. 
 
Fig. 5. ROCK- and PRK-induced contractility is involved in cell-cell contact remodeling. 
A. Human endothelial cells were grown on collagen-coated glass coverslips for 3 days as monolayers, starved 
overnight and then stimulated with thrombin and VEGF. Cell-cell junctions (green) were revealed by either VE-
cadherin or ZO-1 immunostaining.  Nuclei were counterstained by DAPI (magenta). Binary calculation was ap-
plied on threshold pictures to unveil cell-cell morphology (Image J software). Individual cells are numerated 1 to 
4. B. Human endothelial cells were grown on collagen-coated glass coverslips for 3 days as monolayers, starved 
overnight, incubated with anti-VE-cadherin at 4°C for 1h, and then stimulated with thrombin and VEGF at 37°C 
for 30 min. Cells were subjected to a mild acid-wash prior fixation and immunofluorescence. Cells with internal 
acid-resistant staining for VE-cadherin were scored positive when they displayed at least 5 vesicle-like internal 
staining. Graph represents the percentage of cells with VE-cadherin uptake in the total cell population. C. Human 
endothelial cells were grown for 3 days as monolayers, starved overnight and then stimulated with thrombin and 
VEGF. Total cell lysates (TCL) were blotted against phospho-S665 VE-cadherin and total VE-cadherin (VE-cad). 
Phospho-tyrosine (pY), β-catenin (β-cat), β-arrestin2 (β-arr2) and VE-cad western-blots were performed in VE-
cad immunoprecipitation (IP) fractions. D mock-, PRK siRNA- and ROCK-KD-transfected human endothelial 
cells were grown on collagen-coated glass coverslips for 3 days as monolayers, starved overnight and then stimu-
lated with thrombin. VE-cadherin immunostaining is shown in green. Nuclei were counterstained by DAPI (blue). 
Binary calculation (bin.) was applied on threshold pictures to unveil cell-cell morphology (Image J software).  
Individual cells are numerated 1 to 4. All panels are representative of at least 3 independent experiments. ANOVA 
test: *, p<0.05; **, p<0.01; ***, p<0.001. 
 
Fig. 6. Signaling model and molecular mechanisms involved in Thrombin-induced permeability. 
Thrombin induces the activation of its cognate receptor, PAR-1, which is coupled to Gα11/q and Gα12/13 signaling. 
Knockdown experiments showed that Gα11/q is required for both calcium entry and RhoA activation upon throm-
11 
 
bin exposure, while Gα12/13 cooperates in RhoA activation. This dual coupling might regulate the activity and loca-
lization and cycling of multiple Rho GEFs. RhoA is then central in the thrombin-induced increase of permeability 
in endothelial cells, as it triggers the activation of two essential downstream effectors, ROCK and PRK. In addi-
tion, RhoA can control formin activity on actin and microtubule organization. ROCK activity is required for acto-
myosin contractility through the regulation of MLC and cofilin and the actin stress fiber architecture. Conversely, 
PRK expression contributes to FAK and paxillin phosphorylations and the proper focal adhesion morphology. 
Finally, both signaling routes converge on the increase of acto-myosin contractility and cell-cell junction remode-
ling, leading to endothelial barrier destabilization and permeability increase, by a distinct mechanism from that 
initiated by VEGF. 
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3. ROCK and PRK are both required for Thrombin-induced permeability
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4. ROCK and PRK control separately Thrombin-induced contractility pathways
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5. ROCK- and PRK-induced contractility is involved in cell-cell contact remodeling
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6. Signaling model and molecular mechanisms involved in Thrombin-induced permeability
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